Safe Harbor Defense Under 35 U S C 271 E 1 Requires That the Accused Activity Is Solely for Uses Reasonably Related to Submitting Information to the Fda
AMGEN INC. v. HOSPIRA, INC. Before Moore, Bryson, and Chen. Appeal from the United States District Court for the District of Delaware. Summary: Biological engineering activity that would otherwise constitute patent infringement is protected under a safe…
December 17, 2019Federal Circuit2 min read